Medscape

First Clear Win for BTK Inhibitors in Relapsing MS

After previous disappointments with BTK inhibitors, a novel drug in this class is the first to show superiority to an active ...
Healio

FDA approves Tysabri biosimilar Tyruko for relapsing forms of multiple sclerosis

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Tyruko, the first biosimilar to Tysabri injection, for the treatment of adults with ...
Monthly Prescribing Reference

High Dose Ocrelizumab Shows No Added Benefit for Relapsing MS Patients

Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing multiple ...
Yahoo Finance

Sandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Medical Xpress

Rituximab not noninferior to ocrelizumab for relapsing-remitting multiple sclerosis

For patients with relapsing-remitting multiple sclerosis (MS), rituximab is not noninferior to ocrelizumab, according to a study published online June 12 in JAMA Neurology. Izanne Roos, M.B.Ch.B., ...

New synthetic antibiotics could defeat MRSA and prevent relapsing infections

Antibiotic resistance continues to push modern medicine into dangerous territory. In hospitals around the world, infections ...